What bivalirudin intravenous bolus dose and maintenance infusion rate should be used in a patient with a creatinine clearance of 25 mL/min?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bivalirudin Dosing in Severe Renal Impairment (CrCl 25 mL/min)

For a patient with creatinine clearance of 25 mL/min undergoing PCI, administer bivalirudin as a 0.75 mg/kg IV bolus followed by a reduced maintenance infusion of 1.0 mg/kg/h (rather than the standard 1.75 mg/kg/h).

Bolus Dose

The bolus dose remains 0.75 mg/kg IV regardless of renal function 1, 2, 3. This is consistent across all major guidelines and the FDA label. No reduction in the bolus dose is required even in severe renal impairment 3.

Maintenance Infusion Rate

The maintenance infusion must be reduced to 1.0 mg/kg/h in patients with estimated CrCl <30 mL/min 1, 2, 3. The FDA label explicitly states: "Reduce infusion to 1 mg/kg/h with estimated CrCl <30 mL/min" 3. This represents a 43% dose reduction from the standard 1.75 mg/kg/h infusion rate used in patients with normal renal function.

Rationale for Dose Reduction

Bivalirudin undergoes both renal elimination (approximately 20% unchanged drug) and proteolytic cleavage 3, 4. In patients with moderate to severe renal impairment (CrCl <30 mL/min), total body clearance is reduced by approximately 20-24%, and the half-life increases from 25 minutes to 57 minutes 3, 4. This pharmacokinetic alteration necessitates dose reduction to prevent drug accumulation and excessive anticoagulation.

Research data support this dosing strategy. A retrospective study of 64 patients with HIT demonstrated that patients with CrCl <30 mL/min required a median dose of only 0.08 mg/kg/h (range 0.04-0.1 mg/kg/h) to achieve therapeutic aPTT values of 60-80 seconds 5. Another study found patients with CrCl <30 mL/min required 0.05 mg/kg/h compared to 0.13 mg/kg/h in those with normal renal function 6.

Monitoring and Titration

  • Monitor activated clotting time (ACT) during PCI
  • Target ACT: 250-300 seconds (HemoTec device) or 300-350 seconds (Hemochron device) when no GP IIb/IIIa inhibitor is planned 1, 2
  • If GP IIb/IIIa inhibitor is used, target ACT: 200-250 seconds 1, 2
  • An additional bolus of 0.3 mg/kg can be administered if needed to achieve target ACT 1, 2

Critical Considerations

Bleeding risk is substantially elevated in renal dysfunction. Patients with CrCl <60 mL/min have significantly increased risk for in-hospital complications (18.6% vs 2.78%, p=0.011) 7. The combination of advanced age, renal dysfunction, and female gender represents particularly high risk 7.

Do not use standard dosing in renal impairment. The guidelines and FDA label are unequivocal that dose reduction is required. Using the standard 1.75 mg/kg/h infusion in a patient with CrCl 25 mL/min would result in drug accumulation and increased bleeding risk 3.

For patients on hemodialysis: If the patient is dialysis-dependent, reduce the infusion further to 0.25 mg/kg/h during dialysis 8. Approximately 25% of bivalirudin is cleared by hemodialysis, and clearance is reduced by 70% in dialysis patients with a half-life extending to 3.5 hours 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.